Quince Therapeutics Inc. (NASDAQ:QNCX) finished Friday with an addition of $0.06 to close at $0.64, an upside of 10.64 percent. An average of 378,600 shares of common stock have been traded in the last five days. There was a gain of $0.0138 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 289,125 shares traded, while the 50-day average volume stands at 264,180.
QNCX stock has decreased by -13.51% in the last month. The company shares reached their 1-month lowest point of $0.5401 on 12/29/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.54 and a high of $13.70 in 52 weeks. It has reached a new high 1 time so far this year and lost -94.95% or -$11.9826 in price. In spite of this, the price is down -95.35% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Quince Therapeutics Inc. (QNCX) stock’s beta is 1.08. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.22.
The quick ratio of Quince Therapeutics Inc. for the three months ended June 29 was 19.90, and the current ratio was 19.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Quince Therapeutics Inc.’s return on assets was -58.30%.
The analyst consensus anticipated Quince Therapeutics Inc.’s latest quarter earnings to come in at -$0.48 per share, but it turned out to be -$0.51, a -6.30% surprise. For the quarter, EBITDA amounted to -$6.85 million. Shareholders own equity worth $36.13 million.
From a technical analysis perspective, let’s take a brief look at Quince Therapeutics Inc. (QNCX) price momentum. RSI 9-day as of the close on 30 December was 48.82%, suggesting the stock is Neutral, with historical volatility in this time frame at 77.70%.
As of today, QNCX’s price is $0.5983 +2.21% or $0.0138 from its 5-day moving average. QNCX is currently trading -14.67% lower than its 20-day SMA and -70.21% lower than its 100-day SMA. However, the stock’s current price level is -39.30% below the SMA50 and -88.64% below the SMA200.
The stochastic %K and %D were 31.30% and 23.54%, respectively, and the average true range (ATR) was 0.0652. With the 14-day stochastic at 60.89% and the average true range at 0.0666, the RSI (14) stands at 42.85%. The stock has reached -0.0169 on the 9-day MACD Oscillator while the 14-day reading was at -0.0398.
The consensus rating for Quince Therapeutics Inc. (QNCX) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell QNCX, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is QNCX’s price target for the next 12 months?
Analysts predict a range of price targets between $12.00 and $12.00, with a median target of $12.00. Taking a look at these predictions, the average price target given by analysts for Quince Therapeutics Inc. (QNCX) stock is $12.00.